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The Deleted in Malignant Brain Tumors 1 gene
(DMBT1) has been proposed as a tumor suppressor
gene candidate in human brain tumors, based on the
observation of homozygous deletions affecting the
DMBT1 region or part of the gene. In order to support
this hypothesis, we performed a mutational analysis of
the entire coding region of DMBT1, employing SSCP
analysis and direct DNA sequencing in a series of 79
astrocytic gliomas. Five somatic mutations were
detected. Two mutations, one of which resulted in an
amino acid exchange, occurred in glioblastomas. One
pilocytic astrocytoma carried two missense mutations
and another pilocytic astrocytoma contained a somatic
mutation, not affecting the presumed protein. In addition,
21 of the 27 single nucleotide polymorphisms identified in
this study have not been recognized previously. The data
indicate, that small mutations are not a frequent finding
in gliomas.
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The Deleted in Malignant Brain Tumors 1 (DMBT1)
maps to 10q25.3 – q26.1. It is a glycoprotein containing
multiple scavenger receptor cysteine-rich (SRCR)
domains separated by SRCR-interspersed domains
(SID) (Mollenhauer et al., 1997, 1999). Somatic
alterations in genome structure affecting the DMBT1
gene region and loss of DMBT1 gene expression have
been observed in glioblastomas, medulloblastomas
(Mollenhauer et al., 1997) and in non-CNS tumors
such as lung cancers (Takeshita et al., 1999; Wu et al.,
1999) and GI tumors (Mori et al., 1999). In malignant
astrocytic tumors further studies confirmed either
hemizygous or homozygous alterations (Fujisawa et
al., 1999; Sasaki et al., 2001; Somerville et al., 1998;
Steck et al., 1999). So far, systematic analysis of the
entire coding region of DMBT1 in tumors has not yet
been performed since either distinct regions could not
be amplified (Petersen et al., 2000), major portions of
the gene were not included (Takeshita et al., 1999) or
the primer design allowed simultaneous amplification
of multiple amplicons in the highly repetitive regions of
DMBT1 (Wu et al., 1999). Those alterations reported
as a potential point mutation in codon 52 by two
studies (Takeshita et al., 1999; Wu et al., 1999) turned
out to be a single nucleotide polymorphism (SNP) in
our analysis. The prior failure to detect mutations may,
therefore, be due to some mutations residing in regions
not suciently covered by previous analyses. To
analyse the potential role of somatic mutations of
DMBT1 we examined the entire coding region in a
series of 79 astrocytic gliomas, including six pilocytic
astrocytomas WHO grade I (PAI), two pleomorphic
xanthoastrocytomas, seven diffuse astrocytomas WHO
grade II, eight anaplastic astrocytomas WHO grade III
and 56 glioblastoma multiforme WHO grade IV
(GBM). The regulatory sequences upstream of the
DMBT1 gene were not included (Lualdi et al., 2000).
Tumor specimens and corresponding blood samples
were obtained from patients treated at the University
Hospital Bonn and the University Hospital Charite´,
Berlin. The patients have consented to molecular
analysis of the respective tumor and constitutional
DNA. The local ethics committees have approved to
the study design. All tumors were classified according
to the WHO guidelines. Due to the highly repetitive
SRCR and SID domains of DMBT1, nested PCRs
were employed for major portions of the gene. Primer
sequences are available on request. SSCP analysis was
initially restricted to tumor specimens and subsequently
Table 1 Somatic point mutations in the DMBT1 gene
Tissue Exon Nucleotide affected Amino acid
PA I 11 34299 G?T P340P
GBM 13 35282 G?T Q420H
GBM 13 35393 C?T D447D
PA I 18 41469 G?T G620V
41615 C?T R669W
PA I=pilocytic astrocytoma WHO grade I; GBM=glioblastoma
multiforme WHO grade IV; Base pair positions relative to the
DBMT1 gene are numbered according to the GeneBank entry
AJ243211
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extended to constitutional DNA in case of detection of
aberrant bands in tumor DNA.
Five somatic mutations in four astrocytic tumors
were identified affecting exons 11, 13 and 18 of
DMBT1 (see Table 1 and Figure 1). These mutations
were seen in two GBM and PAI each. In GBM ID 418,
nucleotide 35282 in exon 13 of DMBT1 exhibited an
exchange of G?T resulting in an exchange of the
Figure 1 Somatic mutations in the DMBT1 gene. C=DNA from a wild-type control individuals; B=DNA from peripheral blood
leukocytes; Tu=DNA from the corresponding tumor sample. SSCP analysis was performed on a sequencing apparatus (BlueSeq
400, Boehringer Ingelheim, Germany) using 8, 10, 12 and 14% acrylamide gels. Electrophoresis was run at 3 – 6 W and variable
temperatures for 10 – 15 h followed by silver staining. Aberrantly migrating SSCP bands were excised and the DNA was extracted
and purified using the QIAquick gel extraction kit, Qiagen GmbH, Germany, followed by re-amplification with the same set of
primers and sequencing on a semiautomatic sequencer (Applied Biosystems, model 377) using BigDye Terminator Cycle Sequencing
kit (Applied Biosystems). Each amplicon was sequenced bi-directionally
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neutral polar amino acid glutamine for the basic amino
acid histidine Q420H. (Base pair positions relative to
the DMBT1 gene are numbered according to the
sequence AJ243211 published by Mollenhauer et al.
(1997).) PAI ID 20962 exhibited two somatic mutations
in exon 18 affecting nucleotide positions 41469 and
41615 with changes from G?T and C?T resulting in
exchanges of neutral non-polar glycine for neutral non-
polar valine G620V, and of basic arginine for neutral
nonpolar tryptophan R669W. Two of the five muta-
tions did not result in an amino acid exchange. GBM
ID 3902 had a mutation in exon 18, altering nucleotide
position 35393 from C?T with both triplets coding for
aspartic acid 447D. PAI ID 21160 carried a mutation
in exon 11 with nucleotide position 34299 being
exchanged from G?T with both triplets coding for
proline 340P. DNA from peripheral leukocytes exhib-
ited wild-type sequence in the five altered positions in
tumor DNA. DNA identity between tumor and
peripheral leukocytes was confirmed by microsatellite
analysis. The markers D1S1592, D1S1597, D1S1608,
D1S1182 and D19S433 showed identical alleles for
each of the five tumor – blood pairs with the somatic
mutations in the tumor.
Of 27 SNPs, 23 were identified by SSCP analysis and
four were detected by electronic assembly of published
sequence data only. Six of the 23 SNPs identified by
SSCP could be confirmed by electronic assembly.
Twenty-two of the 27 SNPs identified were in coding
and five were in intronic sequences. Splice sites were
not affected. Seven of the SNPs in the coding region
did not result in an altered amino acid sequence. The
SNPs are specified in Table 2. One intronic alteration
to the reference sequence (26096 C?T) was seen in
every case, suggesting either a rare SNP or a reading
error in the reference sequence. Twelve novel exonic
SNPs described in this study were not identified by
electronic assembly, presumably because each SNP was
not covered by more than 10 published sequences. Two
of the six electronically confirmed SNPs were identified
by nested PCR proving the feasibility of the method.
In addition to the deletion polymorphisms, these SNPs
may prove as a valuable tool for genotyping.
These data seem to indicate that small mutations are
rare findings in primary brain tumors and that
homozygous deletions may be the predominant
mechanism of DMBT1 inactivation. In a previous
study we interpreted the loss of DMBT1 sequences in
seven of 32 GBM as evidence for homozygous
deletions (Mollenhauer et al., 1997). However, a recent
study identified the absence of major portions of the
DMBT1 gene in 10 of 36 healthy individuals, thereby
indicating the presence of frequent deletion polymorph-
isms (Mollenhauer et al., 2000). This opens the
Table 2 Single nucleotide polymorphisms (SNPs) in the DMBT1 gene
Allele Allele frequency Exon Nucleotide affected Amino acid
A1/A2 0.641/0.359 2 18532G/A intronic
B1/B2a 0.976/0.024 3c 22681A/C 42T/P
C1/C2 0.994/0.006 4 23392C/G 52S/W
D1/D2a 0.699/0.301 4 23398T/C 54L/S
E1/E2b not determined 4 23416T/C 60V/A
F1/F2 0.300/0.700 5 24807C/T 65P/L
G1/G2b not determined 11 33361A/T 337Q/L
H1/H2 0.904/0.096 13 35091C/T, 35094G/A 357P/S, 358L/L
I1/I2b not determined 13 35112A/G 364R/G
J1/J2 0.993/0.007 16 38637C/A 516G/G
K1/K2 0.994/0.006 18 41452C/T 614A/A
L1/L2a 0.988/0.012 18 41592C/T 662T/M
M1/M2b not determined 21 44923T/C 793T/M
N1/N2a 0.912/0.088 21 44927G/A 794S/S
O1/O2 0.994/0.006 22 46083T/C 855S/S
P1/P2a 0.966/0.034 27 51410C/G 1042V/V
Q1/Q2 0.973/0.027 27 51573C/T 1097H/Y
R1/R2 0.962/0.038 30 54465T/C, 54485C/T 1182M/T, 1189R/W
S1/S2 0.993/0.007 38 65618T/G intronic
T1/T2 0.973/0.027 38 65622T/C intronic
U1/U2 0.987/0.013 39 66591C/T 1557N/N
V1/V2 0.994/0.006 39 66592G/A 1558V/M
W1/W2 0.994/0.006 40 published seq/del 67686-89 intronic
X1/X2 0.963/0.037 42 69800-2 CAG?AGT 1745H/S
Y1/Y2 0.910/0.090 47 79652A/C 1974T/P
Z1/Z2 0.989/0.011 47 79399G/C intronic
a1/a2a 0.491/0.509 54 91604G/A 2348P/P
Allele frequency was determined in 79 astrocytic gliomas and 10 non-astrocytic CNS tumors. There was no difference in allele frequencies
between these groups. aSNPs detected in our series and identified by GenBank assembly; bSNPs identified by GenBank assembly only; cthis SNP
was always associated with three base exchanges in the adjoining introns (22643C/T, 22644T/C and 22707T/A); the allele frequencies for those
SNPs detected in GeneBank only have not been determined. For SNP validation the GeneBank sequence files AJ243211, AB020812, AB020816,
AB020817, AB020818, AB020821, AB020824, AB020827, AB020830, AB020833, AB020836, AB020839, AB020842, AB020843, AB020844,
AB020847, AB020848, AB020849, AB020850, AB020851, AF159456, AJ000342, AJ243212, AJ243224, AJ271916, AJ297935, NM_004406,
NM_007329, NM_017579 and XM_011912 were assembled by utilizing SeqMan II version 4.0 SNPs were defined by at least two different bases
at the same position
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possibility that some of those seven GBM patients
reported with homozygous deletion may have been
either homozygous for one of the recently recognized
deletion polymorphisms or may have carried one of
these variants and lost the other allele due to selection
pressure for another gene defect unrelated to DMBT1.
However, on re-evaluation of those seven GBM we
found only one with homozygous deletions restricted
to the SRCR region harboring the deletion polymorph-
isms. Thus, the other six tumors indeed carried somatic
deletions. However, the role of somatic DMBT1
mutation in GBM is not yet resolved. To further
evaluate the role of inherited deletion polymorphisms
in tumorigenesis, parental blood of the patients needs
to be analysed. Thereby, preferential loss of the allele
harboring the deletion polymorphism could be tested.
However, since the peak incidence of GBM is in the
5th to 7th decade, parental blood is not easily
obtained. Therefore, the patients in the present study
were not analysed for the presence of deletion
polymorphisms or tumor associated homozygous
deletions.
Recent observations suggest that DMBT1gp340 acts
as an opsonin receptor for surfactant protein D in the
immune defense of the lung (Holmskov et al., 1999)
and is involved in epithelial differentiation (Mollen-
hauer et al., 2000). However, tumor suppressor gene
function in a small portion of glial tumors is supported
by our findings and DMBT1 point mutations and
reduced protein expression in primary lung and GI
tumor samples in a parallel study (personal commu-
nication J Mollenhauer). Most alterations locate within
the SRCR/SID region frequently affected by structural
alterations in cancer (Mollenhauer et al., 1999). Yet it
has to be pointed out that only three mutations
detected in our study result in translational changes
and that a considerable portion of all alterations are
caused by deletion polymorphisms (Mollenhauer et al.,
2000). Therefore, only few tumors are characterized by
true somatic mutations. The absolute number of
DMBT1 mutations in the present series is low,
approximating 4% in GBM. However, two of six
patients with PAI exhibited somatic DMBT1 altera-
tions. This contrasts the high frequency of allelic
deletions on chromosomal arm 10q reported for GBM,
a finding rarely seen in PAI (von Deimling et al., 2000).
While DMBT1 mutations in PAI are an unexpected
finding, we have previously identified a PTEN
mutation in a PAI (Duerr et al., 1998), indicating that
involvement of tumor associated genes on chromosome
10 does occur in PAI. Therefore, it may be possible
that DMBT1 plays a role in PAI.
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